Kaya Pai Panandiker is the Chief Commercial Officer of LB Pharmaceuticals, bringing more than 20 years of commercial and operational leadership experience in the global biopharmaceutical industry with deep expertise in neuroscience and related therapeutic areas. She has built and scaled commercial capabilities for first-launch products and led cross-functional teams to drive pipeline value creation and enterprise growth.
Before joining LB Pharmaceuticals, Ms. Pai Panandiker served as Chief Commercial Officer at Neumora Therapeutics and previously as Head of Commercial at Cerevel Therapeutics, where she built the company’s commercial organization and led all pre-launch planning, access, and market preparation during the period leading to its acquisition by AbbVie in 2024.
Earlier, she spent nearly a decade at Lundbeck, holding senior roles including General Manager, U.S. Neuroscience, and Managing Director, Latin America, with full P&L leadership across both regions. In the U.S., she oversaw the launches of REXULTI® and TRINTELLIX® and the bipolar indication for ABILIFY MAINTENA®, delivering blockbuster sales across the neuroscience franchise. In Latin America, she expanded REXULTI® into new markets and built and scaled regional commercial and medical infrastructure, driving growth and profitability across the region and portfolio.
She began her career in strategy consulting before holding commercial roles at Pfizer and Takeda Pharmaceuticals. Ms. Pai Panandiker holds a Master’s degree in Public Policy from the University of Chicago and a Bachelor of Arts from the University of Wisconsin–Madison.
